Abstract
Elucidating how tumor-intrinsic pathways regulate T cell infiltration in tumors is crucial for developing new therapeutic strategies for immune checkpoint blockade therapy. Here, we review recent progress on how these pathways orchestrate immune status in tumors and discuss the potential interventions for reprogramming the tumor microenvironment for cancer treatment.
Keywords:
antitumor immune cycle; conventional type I dendritic cells; immune checkpoint blockade; resistance; tumor microenvironment.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents, Immunological / pharmacology*
-
Antineoplastic Agents, Immunological / therapeutic use
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
B7-H1 Antigen / metabolism
-
Drug Resistance, Neoplasm / drug effects
-
Drug Resistance, Neoplasm / genetics
-
Humans
-
Lymphocytes, Tumor-Infiltrating / drug effects
-
Lymphocytes, Tumor-Infiltrating / immunology*
-
Lymphocytes, Tumor-Infiltrating / metabolism
-
Mutation
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Neoplasms / pathology
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
Programmed Cell Death 1 Receptor / metabolism
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
Tumor Escape / drug effects
-
Tumor Escape / genetics
-
Tumor Microenvironment / drug effects*
-
Tumor Microenvironment / genetics
-
Tumor Microenvironment / immunology
-
Uncoupling Protein 2 / metabolism
Substances
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
UCP2 protein, human
-
Uncoupling Protein 2